Bevacizumab for patients with recurrent gliomas presenting with a gliomatosis cerebri growth pattern

Michael C. Burger*, Iris C. Mildenberger, Marlies Wagner, Michel Mittelbronn, Joachim P. Steinbach, Oliver Bähr

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

7 Citations (Scopus)


Bevacizumab has been shown to improve progression-free survival and neurologic function, but failed to improve overall survival in newly diagnosed glioblastoma and at first recurrence. Nonetheless, bevacizumab is widely used in patients with recurrent glioma. However, its use in patients with gliomas showing a gliomatosis cerebri growth pattern is contentious. Due to the marked diffuse and infiltrative growth with less angiogenic tumor growth, it may appear questionable whether bevacizumab can have a therapeutic effect in those patients. However, the development of nodular, necrotic, and/or contrast-enhancing lesions in patients with a gliomatosis cerebri growth pattern is not uncommon and may indicate focal neo-angiogenesis. Therefore, control of growth of these lesions as well as control of edema and reduction of steroid use may be regarded as rationales for the use of bevacizumab in these patients. In this retrospective patient series, we report on 17 patients with primary brain tumors displaying a gliomatosis cerebri growth pattern (including seven glioblastomas, two anaplastic astrocytomas, one anaplastic oligodendroglioma, and seven diffuse astrocytomas). Patients have been treated with bevacizumab alone or in combination with lomustine or irinotecan. Seventeen matched patients treated with bevacizumab for gliomas with a classical growth pattern served as a control cohort. Response rate, progression-free survival, and overall survival were similar in both groups. Based on these results, anti-angiogenic therapy with bevacizumab should also be considered in patients suffering from gliomas with a mainly infiltrative phenotype.

Original languageEnglish
Article number726
JournalInternational Journal of Molecular Sciences
Issue number4
Publication statusPublished - Apr 2017


  • Anti-angiogenic therapy
  • Bevacizumab
  • Glioblastoma
  • Glioma
  • Gliomatosis cerebri growth pattern
  • Primary brain tumors


Dive into the research topics of 'Bevacizumab for patients with recurrent gliomas presenting with a gliomatosis cerebri growth pattern'. Together they form a unique fingerprint.

Cite this